Moderna raises $110 million in venture round

Preclinical mRNA play Moderna Therapeutics Inc. (Cambridge, Mass.) raised $110 million in an undisclosed venture round led by founding investor Flagship Ventures. Undisclosed existing and new investors also participated. Moderna is developing chemically modified mRNAs that can be delivered by subcutaneous or intramuscular injection and are translated into therapeutic proteins in vivo. The company has several internal programs in preclinical development and said it expects to reach the clinic within the next two years (see BioCentury, Jan. 28). ...